imatinib mesylate has been researched along with Endocrine Gland Neoplasms in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aaron, M; Halperin, DM; Hoff, AO; Hoff, PM; Phan, AT; Yao, JC | 1 |
| Eriksson, B; Eriksson, C; Granberg, D; Gustavsson, B; Janson, ET; Kindmark, H; Kozlowacki, G; Larsson, G; Oberg, K; Skogseid, B; Welin, S | 1 |
| Ackerstein, A; Bitan, M; Gabizon, A; Gross, DJ; Merimsky, O; Munter, G; Salmon, A; Sella, A; Siegal, T; Slavin, S; Weitzen, R | 1 |
3 trial(s) available for imatinib mesylate and Endocrine Gland Neoplasms
| Article | Year |
|---|---|
A phase I study of imatinib, dacarbazine, and capecitabine in advanced endocrine cancers.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Capecitabine; Dacarbazine; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Endocrine Gland Neoplasms; Female; Fluorouracil; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Pyrimidines; Treatment Outcome | 2014 |
Five patients with malignant endocrine tumors treated with imatinib mesylate (Glivec).
Topics: Antineoplastic Agents; Benzamides; Carcinoid Tumor; Endocrine Gland Neoplasms; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Pancreatic Neoplasms; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor | 2010 |
The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Endocrine Gland Neoplasms; Female; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Treatment Outcome | 2006 |